123 related articles for article (PubMed ID: 38916601)
41. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England.
Allen H; Tessier E; Turner C; Anderson C; Blomquist P; Simons D; Løchen A; Jarvis CI; Groves N; Capelastegui F; Flannagan J; Zaidi A; Chen C; Rawlinson C; Hughes GJ; Chudasama D; Nash S; Thelwall S; Lopez-Bernal J; Dabrera G; Charlett A; Kall M; Lamagni T
Epidemiol Infect; 2023 Mar; 151():e58. PubMed ID: 36938806
[TBL] [Abstract][Full Text] [Related]
42. A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants.
Chen CH; Chao DY; Kor CT; Kuo SF; Lin JS; Lai HW; Liu YT; Lin CH; Chen MK
BMC Infect Dis; 2024 May; 24(1):529. PubMed ID: 38802771
[TBL] [Abstract][Full Text] [Related]
43. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
Arashiro T; Miwa M; Nakagawa H; Takamatsu J; Oba K; Fujimi S; Kikuchi H; Iwasawa T; Kanbe F; Oyama K; Kanai M; Ogata Y; Asakura T; Asami T; Mizuno K; Sugita M; Jinta T; Nishida Y; Kato H; Atagi K; Higaki T; Nakano Y; Tsutsumi T; Doi K; Okugawa S; Ueda A; Nakamura A; Yoshida T; Shimada-Sammori K; Shimizu K; Fujita Y; Okochi Y; Tochitani K; Nakanishi A; Rinka H; Taniyama D; Yamaguchi A; Uchikura T; Matsunaga M; Aono H; Hamaguchi M; Motoda K; Nakayama S; Yamamoto K; Oka H; Tanaka K; Inoue T; Kobayashi M; Fujitani S; Tsukahara M; Takeda S; Stucky A; Suzuki T; Smith C; Hibberd M; Ariyoshi K; Fujino Y; Arima Y; Takeda S; Hashimoto S; Suzuki M
Vaccine; 2024 Jan; 42(3):677-688. PubMed ID: 38114409
[TBL] [Abstract][Full Text] [Related]
44. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
46. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Lanièce Delaunay C; Martínez-Baz I; Sève N; Domegan L; Mazagatos C; Buda S; Meijer A; Kislaya I; Pascu C; Carnahan A; Oroszi B; Ilić M; Maurel M; Melo A; Sandonis Martín V; Trobajo-Sanmartín C; Enouf V; McKenna A; Pérez-Gimeno G; Goerlitz L; de Lange M; Rodrigues AP; Lazar M; Latorre-Margalef N; Túri G; Castilla J; Falchi A; Bennett C; Gallardo V; Dürrwald R; Eggink D; Guiomar R; Popescu R; Riess M; Horváth JK; Casado I; García MDC; Hooiveld M; Machado A; Bacci S; Kaczmarek M; Kissling E;
Euro Surveill; 2024 Mar; 29(13):. PubMed ID: 38551095
[TBL] [Abstract][Full Text] [Related]
47. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
48. Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
Zhou H; Zheng H; Peng Y; Su Y; Yu X; Wang W; Li S; Ding Y; Jiao S; Wang Y; Zhu X; Luo L; Dong Z; Liu L; Zhang F; Wu Q; Li J; Zhu F
Front Immunol; 2024; 15():1407826. PubMed ID: 38903523
[TBL] [Abstract][Full Text] [Related]
49. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
[TBL] [Abstract][Full Text] [Related]
50. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
[TBL] [Abstract][Full Text] [Related]
51. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
[TBL] [Abstract][Full Text] [Related]
52. Case clustering, contact stratification, and transmission heterogeneity of SARS-CoV-2 Omicron BA.5 variants in Urumqi, China: An observational study.
Lu Y; Guo Z; Zeng T; Sun S; Lu Y; Teng Z; Tian M; Wang J; Li S; Fan X; Luan Z; Wang W; Cai Y; Wang K; Zhao S
J Glob Health; 2023 May; 13():06018. PubMed ID: 37199483
[TBL] [Abstract][Full Text] [Related]
53. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel.
Prunas O; Warren JL; Crawford FW; Gazit S; Patalon T; Weinberger DM; Pitzer VE
Science; 2022 Mar; 375(6585):1151-1154. PubMed ID: 35084937
[TBL] [Abstract][Full Text] [Related]
54. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
55. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
56. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
[TBL] [Abstract][Full Text] [Related]
57. Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan.
Tomioka K; Uno K; Yamada M
Environ Health Prev Med; 2023; 28():35. PubMed ID: 37286499
[TBL] [Abstract][Full Text] [Related]
58. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
60. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
Jing QL; Liu MJ; Zhang ZB; Fang LQ; Yuan J; Zhang AR; Dean NE; Luo L; Ma MM; Longini I; Kenah E; Lu Y; Ma Y; Jalali N; Yang ZC; Yang Y
Lancet Infect Dis; 2020 Oct; 20(10):1141-1150. PubMed ID: 32562601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
